Click Therapeutics gets FDA authorization for migraine treatment
In a sign of life for the digital therapeutics industry, Click Therapeutics has received FDA authorization for its treatment. The FDA has given marketing authorization for Click’s digital therapeutic...
View ArticleTrump pledges support for changing IRA 'pill penalty,' siding with pharma
President Donald Trump on Tuesday signed an executive order offering support for a change to the IRA's "pill penalty," one of the industry's longstanding policy priorities that could affect billions of...
View ArticleACIP meeting: CDC ‘scraping’ to respond to measles; FDA comments on Novavax
A senior CDC staffer said it's been difficult for the agency to mount a sufficient response to the measles outbreak in Texas that has already killed two children. “We are scraping to find the resources...
View ArticleGeneDx to buy Fabric Genomics for up to $51M
GeneDx is slated to buy Fabric Genomics in a bid to speed up the diagnosis of genetic diseases. The diagnostic company said on Wednesday that it will pay up to $33 million in cash upon ...
View ArticleGlycomine raises $115M to target rare glycosylation disorder
A small California biotech hopes to get its rare disease drug candidate to the FDA's doorstep next year with the help of a $115 million Series C. The funding for Glycomine, disclosed Wednesday morning,...
View ArticleBiotech, CDMOs start to disclose tariff exposure with US trade inquiry underway
Many parts of the pharma supply chain could be at risk as the Commerce Department investigates the sector for potential tariffs. But even before details are ironed out, some biotechs and CDMOs ...
View ArticleAyrmid misses deadline for detailed offer to top private equity bid for bluebird
A rival bid by Ayrmid for bluebird bio hasn't crossed the finish line, the biotech said, after failing to confirm financing by a Tuesday deadline. Ayrmid sought to top a February deal between bluebird...
View ArticleEarly funding for biotechs slumps further in 2025 after several rough years
Port Therapeutics, a nimble biotech with well-known academic and executive names, went to more than 100 investors last year to move beyond the seed stage. But Port’s assets were still too far away from...
View ArticleNovartis terminates knee pain study; Telix reports brain tumor data
Plus, news about Tiger Gene and Theratechnologies: Novartis scraps knee pain drug: The Swiss drugmaker discontinued a Phase 2 test of an under-the-skin treatment for knee osteoarthritis ...
View ArticleTrump drug price executive order: Winners and losers
The biopharma industry saw its first real victory from the Trump administration's Tuesday executive order on drug pricing. The wide-ranging EO offers a first look into the new White House's drug...
View ArticleCDC advisors broaden RSV vaccine recommendations to at-risk adults in their 50s
A CDC advisory panel voted to recommend RSV vaccines for at-risk adults aged 50 to 59, a sought-after expansion by vaccine makers who are trying to grow the market. The vote from the Advisory Committee...
View ArticleCharm Therapeutics founder Laksh Aithani is out as CEO
The London biotech Charm Therapeutics is looking for a new top executive to replace founding CEO Laksh Aithani, Endpoints News has learned. Aithani co-founded the startup in 2021 at the age of 23 along...
View ArticleEli Lilly reports Phase 3 trial win for oral GLP-1 in diabetes
Eli Lilly reported the first Phase 3 data for its oral GLP-1 orforglipron Thursday morning, saying the drug succeeded in a type 2 diabetes trial. The drug hit the primary endpoint of lowering A1C by ...
View ArticleBigHat inks Eli Lilly deal for AI antibody research, extends Series B
BigHat Biosciences has added another pharma partner and more cash to its balance sheet as the antibody specialist prepares to enter the clinic next year. The Bay Area startup will announce a research...
View ArticleSarepta loses CMO to RNA editing upstart; Another wave of personnel moves at...
→ Jacob Elkins has left Sarepta to take the CMO job at AIRNA, the RNA editing shop that disclosed a $155 million Series B earlier this month. The ...
View ArticleNetherlands pours $1.5B into biotech in pursuit of global leadership ambitions
The Dutch government is committing €1.3 billion ($1.5 billion) to support biotech as part of a broader raft of measures designed to make the Netherlands a global leader in the sector by 2040. The...
View ArticleUnitedHealth reports disappointing earnings due to Medicare costs
UnitedHealth Group reported disappointing first-quarter earnings and cut its financial guidance, hit by high costs in its Medicare Advantage business. Though the insurer did not see the same with its...
View ArticleBayer opens $44M US expansion; Meribel CDMO launches in Europe
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Bayer has opened its $44 million 70,000-square-foot expansion at its...
View ArticleSanofi to pay $125M upfront for two immunology drugs from Earendil Labs
Sanofi is teaming up with a private biotech in Delaware on a pair of bispecific antibodies for autoimmune and inflammatory bowel diseases. Sanofi will give $125 million upfront to Earendil Labs for the...
View ArticleWhat it took for Walgreens to go private
This week, Walgreens revealed how its take-private deal came together. Here are some of the biggest takeaways from the filing: There weren't a ton of options for Walgreens ...
View ArticleUS drugs rely heavily on ingredients made overseas — report
Roughly 85% of the brand-name drugs prescribed in the US rely on ingredients sourced from other countries, according to a new report issued ahead of the Trump administration’s expected tariffs on the...
View ArticleRoche discontinues low dose in Huntington’s trial
Roche is stopping patients on the low dose of its experimental Huntington’s drug tominersen, and will be transitioning them to the high dose following recommendations by an independent data monitoring...
View ArticleCMS would absorb 340B drug discount program under leaked HHS proposal
The 340B drug discount program may move under the purview of CMS, according to a leaked HHS restructuring document reviewed by Endpoints News. The 64-page document, first reported on ...
View ArticleGSK's myeloma drug Blenrep wins authorization from UK regulators
The UK on Thursday authorized GSK’s Blenrep to treat certain multiple myeloma patients in two different regimens, marking the drug’s first approval worldwide since it was pulled from the US and other...
View Article